Last reviewed · How we verify
NCT03296605
Development of Obesity and Bariatric Surgery
ENROLLING BY INVITATION
Last updated 23 October 2024
What this trial tests
trial in Obesity in 150 participants. Enrolling by invitation.
Timeline
1 March 2017
Primary endpoint
30 March 2025
30 March 2025
30 June 2025
Quick facts
| Lead sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 150 |
| Start date | 1 March 2017 |
| Primary completion | 30 March 2025 |
| Estimated completion | 30 June 2025 |
| Sites | 1 location across China |
Conditions studied
- Obesity — all drugs for Obesity →
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Who can join
Adults 18 to 75, any sex, with Obesity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study focus on the cause of obesity and impacts of bariatric surgery on it.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Liver governs adipose remodelling via extracellular vesicles in response to lipid overload.
Zhao Y, Zhao MF, Jiang S, Wu J, et al · · 2020 · cited 120× · PMID 32024826 · DOI 10.1038/s41467-020-14450-6 -
Prolactin improves hepatic steatosis via CD36 pathway.
Zhang P, Ge Z, Wang H, Feng W, et al · · 2018 · cited 95× · PMID 29452209 · DOI 10.1016/j.jhep.2018.01.035 -
Hepatic expression of Yin Yang 1 (YY1) is associated with the non-alcoholic fatty liver disease (NAFLD) progression in patients undergoing bariatric surgery.
Yuan X, Chen J, Cheng Q, Zhao Y, et al · · 2018 · cited 15× · PMID 30285651 · DOI 10.1186/s12876-018-0871-2 -
A newly noninvasive model for prediction of non-alcoholic fatty liver disease: utility of serum prolactin levels.
Zhang P, Feng W, Chu X, Sun X, et al · · 2019 · cited 12× · PMID 31775658 · DOI 10.1186/s12876-019-1120-z -
56<sup>th</sup> EASD Annual Meeting of the European Association for the Study of Diabetes : 21-25 September 2020.
· 2020 · cited 9× · PMID 32840677 · DOI 10.1007/s00125-020-05221-5 -
Th1 bias of liver mucosal-associated invariant T cells promotes hepatic gluconeogenesis in type 2 diabetes mellitus.
Tang W, Ge K, Shen L, Wang H, et al · · 2023 · cited 5× · PMID 36738300 · DOI 10.1002/dmrr.3620 -
Elevated mevalonolactone from Ruminococcus torques contributes to metabolically unhealthy obesity development.
Nie HY, Zhao MF, Wu TY, Zou MJ, et al · · 2025 · cited 2× · PMID 40412522 · DOI 10.1016/j.jbc.2025.110281 -
The beneficial effect of hepatic ER stress-associated protein PDI on obesity-associated glucose dysregulation.
Fang D, Yu X, Zhang P, Feng W, et al · · 2025 · PMID 41316343 · DOI 10.1186/s12986-025-01041-9
Verify or expand the search:
- PubMed search for NCT03296605
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Other The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials
Trials by the same sponsor.
- NCT06966765 — Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute D · Phase 3 · not yet recruiting
- NCT07403071 — Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Expe · not yet recruiting
- NCT07532538 — A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions · not yet recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07399574 — Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diqua · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03296605 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Last refreshed: 23 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03296605.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing